Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer

Clin Lung Cancer. 2021 Jan;22(1):e54-e56. doi: 10.1016/j.cllc.2020.07.013. Epub 2020 Aug 5.
No abstract available

Keywords: BRAF inhibitor; Interstitial lung disease; MEK inhibitor; NSCLC.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azetidines / administration & dosage
  • Drug Substitution / methods*
  • Humans
  • Imidazoles / administration & dosage
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutation*
  • Oximes / administration & dosage
  • Piperidines / administration & dosage
  • Prognosis
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / administration & dosage
  • Pyrimidinones / administration & dosage
  • Vemurafenib / administration & dosage

Substances

  • Azetidines
  • Imidazoles
  • Oximes
  • Piperidines
  • Pyridones
  • Pyrimidinones
  • Vemurafenib
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • cobimetinib
  • dabrafenib